Edgewise Therapeutics Appoints Christopher Martin to its Board of Directors

Edgewise Therapeutics (Nasdaq:
EWTX) announced on November 20, 2025, the appointment of Christopher Martin to its Board of Directors.13

Christopher Martin is a seasoned commercial biotech executive with experience in marketing, sales, business development, and product launches.13

Martin previously served as Chief Commercial Officer for Verona Pharma, which was acquired by Merck for approximately $10 billion in October 2025.13

Edgewise cited Martin's expertise as important for preparation of its first commercial launch in Becker muscular dystrophy and to support advancing a key cardiovascular asset to Phase 3 trials.13

Martin has also held senior roles at SK Life Science, Cempra, Salix Pharmaceuticals, and others, and has led multiple commercial launches in the biotech sector.13

He holds a Bachelor of Science in Financial Management from Clemson University.13

The company’s CEO, Kevin Koch, emphasized that Martin’s commercial launch leadership will be critical as Edgewise moves towards key milestones.13

The company’s valuation was noted to be approximately $2.37 billion at the time of the announcement, with significant recent stock performance linked to key advances.2

Sources:

1. https://www.stocktitan.net/news/EWTX/edgewise-therapeutics-appoints-commercial-biotech-executive-pmjfizqbogoj.html

2. https://au.investing.com/news/company-news/edgewise-therapeutics-adds-commercial-biotech-exec-martin-to-board-93CH-4137073

3. https://www.prnewswire.com/news-releases/edgewise-therapeutics-appoints-commercial-biotech-executive-christopher-martin-to-its-board-of-directors-302620999.html